FDA Application Is Submitted for Evaluating HIV Treatment
January 13, 2004
Gilead Sciences Inc. has submitted an investigational new-drug application to the Food and Drug Administration to evaluate GS 9005, a potential protease inhibitor therapy that could be taken once daily. The drug's creator said GS 9005 might have a resistance profile that is distinct from commercially available drugs in the protease inhibitor class. Gilead plans to test the drug in healthy volunteers as well as HIV-positive patients. As an experimental drug, GS 9005 has not been determined to be safe or effective in humans for its intended use, Gilead said.Adapted from:
Wall Street Journal
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.